Circulating tumor cells: Determining its number and what it means by Li, Qiao




circulating tumor cells; cancer diagnostics; cancer therapy
WHEN Steven Paget published his theory of ‘‘seed and soil’’
in 1889 (1), the idea of hematogenous tumor cell dissemina-
tion was born. In many breast cancer patients, circulating cells
with the characteristics of tumor cells can be identified in the
peripheral blood that are known as circulating tumor cells
(CTCs). These cells are present not only in patients with meta-
static disease but also in those whose tumors are apparently
localized (2). It has been reported that tumor cells shed into
the circulation in response to microinvasive events within the
tumor (3). Many of the current research works are therefore
focused on the detection of CTCs in the peripheral venous
blood.
Techniques used to detect CTCs can be generally divided
into cytometric and nucleic acid-based approaches. Cyto-
metric approaches use immunocytochemical methods to iden-
tify and characterize individual tumor cells. For instance, Cris-
tofanilli et al. (4) successfully used the CellSearch System to
detect CTCs. Since then, this method has been used by many
other researchers on breast cancer (5,6). It was also used by
the researchers in the other area. Hristov et al. (7) analyzed
angiogenic monocytes and endothelial progenitor cells (EPC)
for vascular homeostasis in peripheral blood by flow cytome-
try. Nucleic acid-based approaches detect DNA or RNA
sequences that are differentially expressed in tumor cells and
in normal blood components (8). In addition, other techni-
ques have been developed to analyze CTCs. For instance,
Swennenhuis et al. (9) characterized CTCs by fluorescence
in situ hybridization.
The technology of multiparameter flow cytometry
described by Hu et al. (10) in their report published in this
issue is found interesting, because it represents a significant
improvement over the technology that was used by Rehse
et al. (11). In their report, Hu et al. isolated the mononucleo-
cytes and labeled them with monoclonal antibodies anti-
CD45-PerCP, Ep-CAM-PE, and Cytokeratin 8,18,19-FITC in a
similar manner as used by Cristofanilli et al. (4). However, the
enrichment procedure was quite different. By now, most
researchers use immunomagnetic method to enrich mononu-
cleocytes (12). This method often results in significant loses of
target cells. It is expensive, and it involves multiple processes.
All these have made its clinical application difficult. Hu’s
group demonstrated the usefulness and specificity of multi-
parameter flow cytometry in detecting human breast cancer
cells (SKBR-3) in their report. The specificity was significantly
higher compared with traditional RT-PCR analyses, and the
reported high sensitivity limit of 1025 is sensitive enough to
detect the target cells in peripheral blood (12). Hu et al. also
investigated the correlation of overall survival (OS) with the
number of CTCs detected (advanced breast cancer patients:
CTCs  5; limited breast cancer patients: CTCs < 5). The me-
dian OS was 95 weeks and 65.5 weeks for patients with CTCs
< 5 and CTCs  5, respectively. The results of the retrospective
study also demonstrated that the OS was independent of clini-
cal pathology and the tumor size but was closely correlated
with CTC levels as well as age and metastasis. In addition, this
article shows that multiparameter flow cytometry technique is
atraumatic and could be used to detect disease progression
more accurately than imaging. Together, the results presented
in this study using multiparameter flow cytometry to measure
CTCs show great promises for its clinical usage and may there-
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fore provide a novel approach of great value to those who are
in the areas of cancer diagnostics and/or cancer therapy eva-
luations.
Very recently, Goodale et al. (13) used flow cytometry
method to assess monocyte activation markers and circulating
endothelial cells in patients with localized or metastatic breast
cancer. EPCs were successfully used as ‘‘Trojan horses’’ in an
antiangiogenic gene therapy-mediated anticancer strategy for
certain types of malignancies (14). On the basis of its advan-
tages revealed in Hu’s report, multiparameter flow cytometry
may be used in the future to detect the metastasis, help to
choose the appropriate therapy for patients at different stages
and evaluate the prognosis. It is believed that detecting CTCs
in breast cancer patients by using multiparameter flow cyto-
metry has a huge potential to become a valuable tool in clinic.
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